Invesco Biotechnology & Genome ETFPBE
Type
ETF
Peer group
US equity: Healthcare
Net assets
$247.4M
Expense ratio
0.58%
1-year return
+43.9%
3 years, a year
+17.1%
5 years, a year
+4.7%
12-month yield
1.37%
Holdings
33
What it aims to do.
The Invesco Biotechnology & Genome ETF (the Fund) seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome Intellidex Index (the Underlying Index).
Top 10 holdings.
| Holding | % of fund |
|---|---|
| Invesco Private Prime Fund | 10.92% |
| UTHR United Therapeutics Corp. | 6.29% |
| ILMN Illumina, Inc. | 5.37% |
| BIIB Biogen Inc. | 5.05% |
| INCY Incyte Corp. | 4.91% |
| ALNY Alnylam Pharmaceuticals, Inc. | 4.84% |
| REGN Regeneron Pharmaceuticals, Inc. | 4.77% |
| AMGN Amgen Inc. | 4.71% |
| GILD Gilead Sciences, Inc. | 4.61% |
| Invesco Private Government Fund | 4.20% |
More on PBE.
- PBE overview
- PBE holdings
- PBE risk
- PBE costs
- PBE money in and out
- PBE share classes
- Compare PBE with other funds
Returns after fees, from the fund's SEC filings up to Aug 2026. Past returns are not a promise. Not financial advice.